Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH

Treatment of Nonalcoholic fatty liver disease (NAFLD) constitutes an unmet clinical need owing to the relatively limited efficacy of both novel and readily available metabolic medications, thus warranting pathobiological investigations on the mechanisms of single or combination regimens. In this con...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Autores principales: Perakakis, Nikolaos, Stefanakis, Konstantinos, Feigh, Michael, Veidal, Sanne S, Mantzoros, Christos S
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2021
Materias:
Cardiovascular Endocrinology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089912/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.642
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares